login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
MOLECULIN BIOTECH INC (MBRX) Stock News
USA
- NASDAQ:MBRX -
US60855D3098
-
Common Stock
0.51
USD
+0.03 (+5.72%)
Last: 10/17/2025, 8:26:53 PM
0.509
USD
0 (-0.2%)
Pre-Market:
10/20/2025, 7:08:21 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
MBRX Latest News, Press Relases and Analysis
All
Press Releases
25 days ago - By: Moleculin Biotech, Inc.
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
a month ago - By: Benzinga
- Mentions:
ADAP
LYRA
ADTX
ALXO
...
12 Health Care Stocks Moving In Thursday's After-Market Session
a month ago - By: Zacks Investment Research
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
a month ago - By: Moleculin Biotech, Inc.
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
a month ago - By: Moleculin Biotech, Inc.
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
2 months ago - By: The Motley Fool
Moleculin Biotech Misses Fiscal Q2 EPS
4 months ago - By: Benzinga
- Mentions:
CPRX
RCEL
Top 3 Health Care Stocks You'll Regret Missing This Quarter
4 months ago - By: Moleculin Biotech, Inc.
Moleculin Participates in Virtual Investor “What This Means” Segment
2 months ago - By: Moleculin Biotech, Inc.
Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds
2 months ago - By: Moleculin Biotech, Inc.
Moleculin Issues New Positive AML Overall Survival Data:
2 months ago - By: Moleculin Biotech, Inc.
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
2 months ago - By: Moleculin Biotech, Inc.
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
2 months ago - By: Moleculin Biotech, Inc.
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
3 months ago - By: Moleculin Biotech, Inc.
Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
3 months ago - By: ACCESS Newswire
- Mentions:
AKTX
AMIX
CNSP
NVNO
...
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
3 months ago - By: Moleculin Biotech, Inc.
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
3 months ago - By: Moleculin Biotech, Inc.
Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans
4 months ago - By: Yahoo Finance
Moleculin Biotech prices 16.08M shares at 37c in public offering
4 months ago - By: Moleculin Biotech, Inc.
Moleculin Announces $5.9 Million Public Offering
Please enable JavaScript to continue using this application.